CD40-Activated B Cell Cancer Vaccine Improves Second Clinical Remission and Survival in Privately Owned Dogs with Non-Hodgkin's Lymphoma

Cell-based active immunotherapy for cancer is a promising novel strategy, with the first dendritic cell (DC) vaccine achieving regulatory approval for clinical use last year. Manufacturing remains arduous, especially for DC vaccines, and the prospect of using cell-based immunotherapy in the adjuvant...

Descripción completa

Detalles Bibliográficos
Autores principales: Sorenmo, Karin U., Krick, Erika, Coughlin, Christina M., Overley, Beth, Gregor, Thomas P., Vonderheide, Robert H., Mason, Nicola J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3164165/
https://www.ncbi.nlm.nih.gov/pubmed/21904611
http://dx.doi.org/10.1371/journal.pone.0024167

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3164165/
https://www.ncbi.nlm.nih.gov/pubmed/21904611
http://dx.doi.org/10.1371/journal.pone.0024167

Ejemplares similares